Sökning: WFRF:(Pozniak Anton)
> (2014) >
Ritonavir-boosted d...
-
Raffi, FrançoisUniversity of Nantes
(författare)
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1 : 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
- Artikel/kapitelEngelska2014
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:b5cc5f2a-c64d-43f3-91ec-8267746aa636
-
https://lup.lub.lu.se/record/b5cc5f2a-c64d-43f3-91ec-8267746aa636URI
-
https://doi.org/10.1016/S0140-6736(14)61170-3DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:130162442URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
BACKGROUND: Standard first-line antiretroviral therapy for HIV-1 infection includes two nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs), but these drugs have limitations. We assessed the 96 week efficacy and safety of an NtRTI-sparing regimen.METHODS: Between August, 2010, and September, 2011, we enrolled treatment-naive adults into this randomised, open-label, non-inferiority trial in treatment-naive adults in 15 European countries. The composite primary outcome was change to randomised treatment before week 32 because of insufficient virological response, no virological response by week 32, HIV-1 RNA concentration 50 copies per mL or higher at any time after week 32; death from any cause; any new or recurrent AIDS event; or any serious non-AIDS event. Patients were randomised in a 1:1 ratio to receive oral treatment with 400 mg raltegravir twice daily plus 800 mg darunavir and 100 mg ritonavir once daily (NtRTI-sparing regimen) or tenofovir-emtricitabine in a 245 mg and 200 mg fixed-dose combination once daily, plus 800 mg darunavir and 100 mg ritonavir once daily (standard regimen). This trial was registered with ClinicalTrials.gov, number NCT01066962.FINDINGS: Of 805 patients enrolled, 401 received the NtRTI-sparing regimen and 404 the standard regimen, with median follow-up of 123 weeks (IQR 112-133). Treatment failure was seen in 77 (19%) in the NtRTI-sparing group and 61 (15%) in the standard group. Kaplan-Meier estimated proportions of treatment failure by week 96 were 17·8% and 13·8%, respectively (difference 4·0%, 95% CI -0·8 to 8·8). The frequency of serious or treatment-modifying adverse events were similar (10·2 vs 8·3 per 100 person-years and 3·9 vs 4·2 per 100 person-years, respectively).INTERPRETATION: Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL.FUNDING: European Union Sixth Framework Programme, Inserm-ANRS, Gilead Sciences, Janssen Pharmaceuticals, Merck Laboratories.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Babiker, Abdel G.University College London
(författare)
-
Richert, LauraUniversity of Bordeaux
(författare)
-
Molina, Jean-MichelParis Diderot University,Saint-Louis Hospital, Paris
(författare)
-
George, Elizabeth C.University College London
(författare)
-
Antinori, AndreaLazzaro Spallanzani National Institute for Infectious Diseases
(författare)
-
Arribas, Jose RUniversity Hospital La Paz
(författare)
-
Grarup, JesperUniversity of Copenhagen,Copenhagen University Hospital
(författare)
-
Hudson, FleurUniversity College London
(författare)
-
Schwimmer, ChristineUniversity of Bordeaux
(författare)
-
Saillard, JulietteANRS - France Recherche Nord & Sud Sida-HIV Hépatites virales
(författare)
-
Wallet, CédrickUniversity of Bordeaux
(författare)
-
Jansson, Per O.University of Copenhagen
(författare)
-
Allavena, ClotildeUniversity of Nantes
(författare)
-
Van Leeuwen, RemkoAcademic Medical Center of University of Amsterdam (AMC),Amsterdam Institute for Global Health and Development
(författare)
-
Delfraissy, Jean-FrançoisBicêtre Hospital
(författare)
-
Vella, StefanoItalian National Institute of Health (ISS)
(författare)
-
Chêne, GenevièveUniversity of Bordeaux
(författare)
-
Pozniak, AntonChelsea and Westminster Hospital
(författare)
-
Odermarsky, MichalLund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)mi1050od
(författare)
-
University of NantesUniversity College London
(creator_code:org_t)
-
NEAT001/ANRS143 Study Group
Sammanhörande titlar
-
Ingår i:The Lancet384:9958, s. 51-19421474-547X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Raffi, François
-
Babiker, Abdel G ...
-
Richert, Laura
-
Molina, Jean-Mic ...
-
George, Elizabet ...
-
Antinori, Andrea
-
visa fler...
-
Arribas, Jose R
-
Grarup, Jesper
-
Hudson, Fleur
-
Schwimmer, Chris ...
-
Saillard, Juliet ...
-
Wallet, Cédrick
-
Jansson, Per O.
-
Allavena, Clotil ...
-
Van Leeuwen, Rem ...
-
Delfraissy, Jean ...
-
Vella, Stefano
-
Chêne, Geneviève
-
Pozniak, Anton
-
Odermarsky, Mich ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Infektionsmedici ...
- Artiklar i publikationen
-
The Lancet
- Av lärosätet
-
Lunds universitet
-
Karolinska Institutet